You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Icotinib

Showing 1 - 25 of 103
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, EGFR Sensitive Mutation, Adjuvant Therapy Trial in Beijing, Nanjing, Shanghai (Befotertinib + Icotinib , Icotinib +

Recruiting
  • Non-Small Cell Lung Cancer
  • +2 more
  • Befotertinib + Icotinib placebo
  • Icotinib + Befotertinib placebo
  • Beijing, China
  • +2 more
Sep 20, 2023

NSCLC Trial (Icotinib)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Icotinib
  • (no location specified)
Aug 23, 2022

NSCLC Trial in Beijing (Icotinib)

Completed
  • Non-small Cell Lung Cancer
  • Icotinib
  • Beijing, Beijing, China
    Xuanwu Hospital, Capital Medical University
Jan 24, 2022

NSCLC, Bevacizumab, EGF-R Positive NSCLC Trial in Tianjin (Bevacizumab, Icotinib)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +3 more
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Mar 2, 2022

NSCLC, EGF-R Positive NSCLC Trial in Shenyang (Icotinib, Cisplatin, Carboplatin)

Not yet recruiting
  • NSCLC
  • EGF-R Positive Non-Small Cell Lung Cancer
  • Icotinib
  • +3 more
  • Shenyang, Liaoning, China
    Liaoning Cancer Hospital & Institute
Nov 28, 2021

Vestibular Schwannoma, Neurofibromatosis Type 2 Trial in Beijing (Icotinib)

Completed
  • Vestibular Schwannoma
  • Neurofibromatosis Type 2
  • Icotinib
  • Beijing, Beijing, China
  • +1 more
Sep 8, 2021

NSCLC Trial in Beijing (Icotinib, Cisplatin, Carboplatin)

Recruiting
  • Non-Small Cell Lung Cancer
  • Icotinib
  • +3 more
  • Beijing, China
    BeijingCancerH
Nov 2, 2021

NSCLC Trial in Xiamen (Icotinib, Befotertinib)

Recruiting
  • Non-Small Cell Lung Cancer
  • Xiamen, Fujian, China
    Feng Ye
Sep 17, 2021

Lung Tumors, Squamous Cell Lung Cancer, Adenocarcinoma of the Lung Trial in Guangzhou (Icotinib)

Recruiting
  • Lung Neoplasms
  • +6 more
  • Icotinib
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Jul 29, 2021

Non Small Cell Lung Cancer Trial in Tianjin (Anlotinib, Icotinib)

Recruiting
  • Non Small Cell Lung Cancer
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Mar 12, 2021

NSCLC, EGFR Gene Mutation Trial in Hangzhou, Liuzhou (D-0316 Capsule, Icotinib Hydrochloride Tablets)

Active, not recruiting
  • Non-Small Cell Lung Cancer
  • EGFR Gene Mutation
  • D-0316 Capsule
  • Icotinib Hydrochloride Tablets
  • Hangzhou, Zhejiang, China
  • +1 more
May 10, 2021

NSCLC Trial in China (Icotinib, Chemotherapy)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • Beijing, Beijing, China
  • +7 more
Jul 14, 2021

Metastatic Breast Cancer Trial in Guangzhou (Icotinib)

Terminated
  • Metastatic Breast Cancer
  • Icotinib
  • Guangzhou, Guangdong, China
    Sun Yat-sen University, Cancer Center
Jan 26, 2021

Non Small Cell Lung Cancer Trial in Shijiazhuang, Hohhot, Tianjin (Anlotinib Plus Icotinib)

Completed
  • Non Small Cell Lung Cancer
  • Anlotinib Plus Icotinib
  • Shijiazhuang, Hebei, China
  • +4 more
Mar 11, 2021

Lung Adenocarcinoma Trial in Zhengzhou (Icotinib, Pemetrexed/Carboplatin)

Unknown status
  • Lung Adenocarcinoma
  • Zhengzhou, Henan, China
    Henan cancer hospital
Jun 30, 2020

Lung Tumors Trial (Cryotherapy, Icotinib)

Completed
  • Lung Neoplasms
  • Cryotherapy
  • Icotinib
  • (no location specified)
May 24, 2020

Bevacizumab Plus EGFR-TKIs in Chinese EGFR-mutant

Recruiting
  • NSCLC
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's Hospital
Oct 17, 2020

Non Small Cell Lung Cancer, Brain Metastases Trial in Hangzhou (Icotinib, SRS/WBRT/HA-WBRT/SMART)

Unknown status
  • Non Small Cell Lung Cancer
  • Brain Metastases
  • Icotinib
  • SRS/WBRT/HA-WBRT/SMART
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Aug 13, 2019

MRD Trial in China (Adjuvant treatment for MRD positivity)

Recruiting
  • MRD
  • Adjuvant treatment for MRD positivity
  • Beijing, China
  • +15 more
Sep 12, 2022

Adenocarcinoma of the Gastroesophageal Junction, Esophageal Carcinoma Trial in Beijing (Icotinib)

Completed
  • Adenocarcinoma of the Gastroesophageal Junction
  • Esophageal Carcinoma
  • Icotinib
  • Beijing, Beijing, China
    Cancer Hospital, Chinese Academy of Medical Sciences
Jul 2, 2019

Lung Adenocarcinoma, EGFR Activating Mutation Trial (icotinib combined with pemetrexed plus cisplatin, first icotinib and then

Completed
  • Lung Adenocarcinoma
  • EGFR Activating Mutation
  • icotinib combined with pemetrexed plus cisplatin
  • first icotinib and then pemetrexed plus cisplatin
  • (no location specified)
Oct 11, 2019

NSCLC Trial (Icotinib, Placebo, chemo)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Icotinib
  • +2 more
  • (no location specified)
Jun 11, 2019

Stage IV NSCLC Trial in Wuhan (SBRT+TKI, TKI)

Completed
  • Stage IV Non-small Cell Lung Cancer
  • Wuhan, Hubei, China
    Tongji Hospital of Tongji Medical College of Huazhong University
Apr 5, 2021

NSCLC, Brain Metastases Trial in Chengdu (Icotinib, SRS)

Recruiting
  • Non-small Cell Lung Cancer
  • Brain Metastases
  • Icotinib
  • SRS
  • Chengdu, Sichuan, China
    West China Hospital
Feb 15, 2019

NSCLC, Brain Metastases Trial (Icotinib, WBRT or SRS)

Unknown status
  • Non-Small Cell Lung Cancer
  • Brain Metastases
  • Icotinib
  • WBRT or SRS
  • (no location specified)
Nov 26, 2018